ValiRx Regulatory News (VAL)

25 April 2013

ValiRx Plc

("ValiRx" or the "Company")

Patent Granted for Lead Therapeutic Compound VAL201

ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that a patent covering its lead therapeutic compound VAL201 has been granted in Australia.

VAL201 has shown efficacy in prostate, breast and ovarian cancer models as well as addressing endometriosis or hormone induced abnormal cell growth in women. Based on results in endometrial models, VAL201 has been shown to reduce the abnormal endometrial growth, whilst leaving other hormone-induced activities working normally. The compound is currently progressing well through its clinical development.

The original patent and technology covering VAL201 is licensed by ValiRx from Cancer Research Technology ("CRT") for use in androgen resistant cancer. ValiRx has all rights to perform pre-clinical and clinical developments and obtaining regulatory approvals in all territories. ValiRx also has full, worldwide rights and control over the commercialisation and development of potential treatments.

Dr Satu Vainikka, Chief Executive, commented:"

"The granting of this latest patent means that ValiRx is able to add to the Company's intellectual property assets and extend its already extensive IP protection for this compound and its intended indications."

- ENDS -

For more information, please contact:

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

ValiFinn is the biomarkers and diagnostic development division

ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.